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The Dacron sewing ring material of the St. Jude Medical mechanical heart 
valve (St. Jude Medical, Inc., St. Paul, Minn.) was passively impregnated 
with rifampicin (60 mg/ml) both in its unsealed state and after sealing by 
the methods of preclotting in blood, autoclaving in blood, and autoclaving 
in 20% albumin. Antistaphylococcal activity in the Dacron material was 
assessed immediately after rifampicin impregnation and at regular periods 
up to 5 days after implantation into the goat aorta. When the Dacron 
material had been sealed by autoclaving in blood and autoclaving in 20% 
albumin significant retention of antistaphylococcal ctivity was found after 
5 days in vivo. Best results were obtained with the use of autoclaved blood 
(p < 0.05). We also compared these results with those obtained from 
impregnating commercially available gelatin-sealed (Gelseal) and collagen- 
sealed (Hemashield) Dacron material with rifampicin. Although anti- 
staphylococcal ctivity was equivalent immediately after rifampicin impreg- 
nation, after 4 days in vivo the activity was negligible in Gelseal material 
(p < 0.05) and could not be demonstrated in Hemashield material. 
Rifampicin impregnation of the intact St. Jude Medical mechanical valve 
sewing ring may have an application in the prevention of prosthetic valve 
endocarditis and a clinical protocol is suggested. (J Thorac Cardiovasc 
Surg 1996;112:248-52) 
C ardiac valve replacement in the setting of active endocarditis carries a significant risk of persist- 
ing infection on the replacement device. 1Operation 
for aortic valve endocarditis i currently best man- 
aged with use of an aortic valve allograft. 2 However, 
aortic valve allografts of the appropriate size are not 
always readily available in most cardiac surgical 
centers, especially in an emergency. In addition, 
patients with mitral valve endocarditis may not have 
conditions amenable to repair and consequently 
valve replacement with a prosthetic device is neces- 
sary. Therefore many patients with endocarditis 
undergo valve replacement with a mechanical or 
bioprosthetic valve. In such instances, prosthetic 
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valve endocarditis (PVE), recurrent or persisting, 
will be an ever-present risk in the early postopera- 
tive phase. 2
Bearing in mind that the site of infection in PVE 
is predominantly on the sewing ring, we postulated 
that a sewing ring resistant to early infection would 
significantly reduce the prevalence of PVE in pa- 
tients at high risk. Previous studies by others have 
demonstrated that rifampicin can be passively incor- 
porated into Dacron graft material. 3-9 This ability 
has not been found with many other antibiotics. It 
has been shown that rifampicin can be ionically or 
covalently bound to an appropriate sealant such as 
human serum proteins, collagen, or gelatin that is 
bonded as a film to the Dacron graft material, which 
then acts as an antibiotic release system. For exam- 
ple, the N-4 piperazine group of rifampicin binds 
covalently to available carboxyl residues on gelatin 
in gelatin-sealed Dacron graftsJ ° The retention of 
rifampicin activity in the prosthetic graft must then 
depend both on the affinity of the antibiotics for the 
graft sealant and on the rate of disappearance of the 
latter after implantation. 
Sealing is a term that stems from the early role 
such treatments originally had in making the graft 
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impervious to blood by coating the material with a 
film of protein. 
This study attempts to evaluate the incorporation 
and retention of rifampicin into the Dacron sewing 
ring of the St. Jude Medical heart valve in an in vivo 
animal model. 
Material and methods 
The St. Jude Medical heart valve (St. Jude Medical, 
Inc., St Paul, Minn.) has a sewing ring constructed from 
unsealed double-velour knitted Dacron material. Eight 
millimeter discs of this material were made with a stan- 
dard-sized punch. These discs were either left unsealed or 
sealed by one of the following methods: (1) preclotting 
with autologous blood, (2) autoclaving for 2 minutes with 
autologous blood, or (3) autoclaving for 2 minutes with 
20% albumin. Rifampicin (Marion Merrell Dow, Pty. 
Ltd., Sydney, Australia) was made up to a solution of 60 
mg/ml in sterile 0.9% NaC1. The discs were then soaked in 
the rifampicin solution at room temperature for 15 min- 
utes before goat intra-aortic implantation. 
In addition, gelatin-sealed knitted Dacron material 
(Gelseal Triaxial, Vascutek, Renfrenshire, Scotland) and 
woven double-.velour collagen-sealed Dacron material 
(Hemashield, Meadox Inc., Oakland, N.J.) were also used 
to compare the uptake and retention of rifampicin in 
these materials with that of the sewing ring material from 
the St. Jude Medical valve. Eight millimeter discs were cut 
and impregnated with rifampicin solution as described 
herein. 
The antistaplaylococcal activity in each disc was assessed 
(see microbiologic method section) according to the fol- 
lowing design: (1) immediately after rifampicin impregna- 
tion (rifampicin uptake), (2) after 1 hour in vivo, (3) after 
1 day in vivo, (4) after 2 days in vivo, (5) after 3 days in 
vivo, (6) after 4 days in vivo, and (7) after 5 days in vivo. 
Control discs sealed by the methods described but neither 
impregnated with rifampicin nor surgically implanted 
were also assessed for any inherent antistaphylococcal 
activity. 
Animal study protocol. The in vivo component of the 
study was done in female Cashmere goats. A total of seven 
goats was used. Each goat was anesthetized with intrave- 
nous thiopenta!, intubated, and maintained on a 1.5% 
halothane/oxygen mixture. With use of sterile surgical 
technique and through a left thoracotomy the discs of 
rifampicin-impregnated Dacron material were secured to 
the luminal aspect of the descending thoracic aorta by a 
single horizontal mattress uture. Discs in triplicate, at 
least 1 cm apart, sealed by each method were implanted 
into the aorta at a different level through a separate 
aortotomy. The goat in which the rifampicin-impregnated 
discs were kept for 1 hour remained anesthetized with the 
chest open for 1 hour after release of the aortic cross- 
clamps, whereupon it was killed with pentobarbital nd 
the discs recovered. The other goats were all removed 
from the anesthetic and extubated. Intercostal nerve 
blocks with 0.5% bupivacaine were administered to each 
of these goats while the chest was being closed. All 
animals remained undistressed and made a good recovery 
from the thoracotomy. At the time intervals after implan- 
tation of 1 day, 2 days, 3 days, 4 days, and 5 days, the discs 
were recovered (after the goats were killed with pento- 
barbital) and assessed for antistaphylococcal activity. A 
single goat was the vehicle for all the discs for each period 
with one exception: two goats were used to carry discs for 
4 days because our acquisition of the commercially avail- 
able collagen-sealed Dacron material occurred after the 
other methods had already been assessed at 4 days. 
Microbiologie method. Antistaphyl0coccal activity was 
assayed by placing the discs on an agar plate that had been 
inoculated for confluent growth of Staphylococcus aureus 
(strain ATCC25923, inoculum at 10 7 colony-forming units 
per milliliter ). The area of inhibition of growth around the 
disc at 24 hours was measured. 
Tissue culture method. The effect of rifampicin on the 
tissue culture of fibroblasts from goat aorta and pericar- 
dium was also assessed. Before culture study, pieces of 
aortic or pericardial tissue were soaked in rifampiein 
solution (60 mg/ml, 0.9% NaC1) at room temperature for 
15 minutes. Chopped tissue pieces were cultured in me- 
dium 199 plus 10% fetal calf serum (CSL Ltd., Victoria, 
Australia) in 5% CO 2 at 37°C for 3 weeks. The subse- 
quent outgrowth of fibroblasts was compared with that 
from untreated tissue. 
Care of experimental animals. All animals received 
humane care in compliance with the principles of animal 
care as formulated by The National Health and Medical 
Research Council (Australia). This experimental study 
was approved by The Prince Charles Hospital Animal 
Ethics Committee (approval AEEC0693-02). 
Statistical methods. Antistaphylococcal ctivity was 
measured as the mean area (in square centimeters) of 
growth inhibition on the agar plates from triplicate discs. 
The error was expressed as the range observed, with an 
accuracy in measuring the diameters of -+ 1 mm. Nonpara- 
metric statistical methods were used to analyze the data. 
The Kruskal-Wallis test was used to establish whether 
there was a difference between methods at all times. The 
Mann-Whitney U test was used to compare specific 
methods. The level of significance used was c~ = 0.05. 
Results 
No antistaphylococcal activity was demonstrated 
in the control discs not impregnated with rifampicin, 
regardless of the sealant present. 
Table I shows the rifampicin uptake, as expressed 
by antistaphylococcal activities at time 0, for each of 
the methods used to seal the Dacron discs. The 
Kruskal-Wa!lis test verified a significant difference 
in the methods used (including and excluding the 
control discs). The highest levels of antistaphylococ- 
cal activity were observed in Dacron material sealed 
with autoclaved blood and autoclaved albumin. The 
Mann-Whitney U test was not able to identify one 
method as being consistently significantly better 
than the others; however, a subgrouping of Dacron 
discs sealed with autoclaved blood and autoclaved 
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Fig. 1. Loss of rifampicin from Dacron discs measured as 
antistaphylococcal activity (inhibition of growth ) for three 
methods of sealing Dacron sewing ring material and for 
unsealed Dacron material. Value for control discs is also 
plotted. 
albumin versus a subgrouping of all the other meth- 
ods demonstrated a highly significant difference 
(p = 0.0056, Table I). 
The loss of rifampicin antistaphylococcal activity 
from the discs over 5 days in vivo is shown in Figs. 1 
and 2. Unsealed Dacron material impregnated with 
rifampicin lost most of its initial activity after only 1 
hour in vivo. Similarly, for Dacron material sealed 
with clotted blood, there was a substantial loss of 
antistaphylococcal activity after 1 hour in vivo, de- 
spite the initial moderately high level of activity 
demonstrated before implantation. Dacron material 
sealed with autoclaved blood, however, still demon- 
strated a moderate level of antistaphylococcal activ- 
ity after 5 days in vivo. Statistically equivalent anti- 
staphylococcal ctivity was seen for up to 2 days 
between Dacron discs sealed with autoclaved blood 
and autoclaved 20% albumin; however, by day 4 the 
former method proved to retain a significantly 
higher level of activity. Nevertheless, activity could 
still be demonstrated with Dacron material sealed 
with autoclaved albumin after 5 days in vivo (Fig. 1). 
The antistaphylococcal activity in gelatin-sealed 
Dacron discs had fallen to almost negligible levels 
after 4 days; however, this was significantly higher 
than activity in Dacron discs sealed with collagen, 
which could not be demonstrated at 4 and 5 days 
after implantation (Fig. 2). 
The difference demonstrated at time 0 between 
the two subgroups continued to be significant at all 
subsequent times. 
Large numbers of fibroblasts were able to be 
cultured from both goat aorta and pericardium. 
Table I. Rifampicin uptake 
Sealing Inhibition: Mean 
method area (era 2) (range) Subgroup 
Autoclaved in blood 20.34 (14.69-24.11) 1 
Autoclaved in 20% albumin 21.34 (18.34-24.11) 1 
Gelatin sealed 18.95 (16.84-21.65) 2 
Preclotted in blood 15.40 (14.70-16.11) 2 
Collagen sealed 15.02 (11.44-18.34) 2 
Unsealed 12.06 (11.44-12.70) 2 
Control 0 0 
Uptake of rifampicin by the Dacron sewing ring material measured as 
antistaphylococcal activity (inhibition of growth) at time 0 for unsealed 
Dacron material, the five sealant methods, and the control discs (not 
rifampicin soaked). 
Although growth was not assayed quantitatively, 
rifampicin did greatly diminish the outgrowth of 
fibroblasts from the rifampicin-soaked tissue pieces. 
Discussion 
PVE is an important complication of prosthetic 
valve replacement for endocarditis. It has recently 
been reported that the 1-year freedom from PVE in 
this setting is 87%. 11 Infection predominantly affects 
the host tissues attaching to the sewing ring of the 
prosthesis, although in bioprosthetic valves it can 
affect the leaflet tissue. The ability to retain local 
antibacterial activity in the sewing ring of a pros- 
thetic valve might therefore decrease the risk of 
PVE in the period immediately after valve implan- 
tation. 
Powell, Burnham, and Johnson 3added rifampicin 
to the blood used for preclotting the Dacron mate- 
rial rather than soaking the clotted graft as we have 
done. This resulted in good retention 24 hours after 
implantation into the dog. Other workers have 
attempted to duplicate these experiments by using 
commercially available sealed Dacron fabric arterial 
grafts and simulating in vivo conditions by agitating 
the rifampicin-loaded Dacron material in an albu- 
min/saline solution mixture. 7'8 With these tech- 
niques Chervu and associates 7 found that rifampi- 
cin-impregnated collagen-sealed grafts retained 
antistaphylococcal activity for 22.4 days, which was 
significantly better than the duration of antistaphy- 
lococcal activity in rifampicin-impregnated pre- 
clotted grafts. This result was not supported in a 
study by Ashton and colleagues, 8 who found that 
rifampicin activity in collagen-sealed grafts could 
only be demonstrated for 1 day of simulated in vivo 
conditions, but with gelatin-sealed grafts the activity 
could be demonstrated for up to 4 days. 
Our results were obtained with the use of true in 
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vivo conditions. They do support the finding that 
rifampicin appears to be better etained in gelatin- 
sealed Dacron material than in collagen-sealed Da- 
cron material,, although we recognize that our study 
did not fully assess these grafts in the initial few days 
of the in vivo period. More important, however, we 
found that better etention occurs when rifampicin 
is added to Dacron material that has first been 
sealed by autoclaving in the animal's blood and, to a 
somewhat lesser extent, by autoclaving in 20% albu- 
min. In addition, our results show that the auto- 
claved blood technique yields significantly better 
antistaphylococcal activity after 4 and 5 days in vivo 
than the autoclaved 20% albumin technique. 
One problem encountered with the Dacron discs 
sealed by autoclaving in blood was an increased 
resistance of the material to needle penetration. 
This may be of some concern, inasmuch as the 
unsealed St. Jude Medical valve sewing ring by itself 
does not permit easy needle passage. Neither auto- 
claving in 20% albumin nor the presence of gelatin 
or collagen appears to affect he handling character- 
istics of the Dacron material. 
We would point out that the techniques described of 
sealing Dacron material by autoclaving in blood or 
albumin, when applied to the intact valve, carry a risk 
of causing paniculate matter to adhere to the valve 
leaflets, which may interfere with leaflet function or 
could possibly affect he prevalence of valve thrombo- 
sis. This problem can be overcome by ensuring that no 
blood remains on the valve leaflets before autoclaving 
and that the leaflets are meticulously cleaned of all 
particulate matter after autoclaving. 
The unfavorable ffect of rifampicin on fibroblast 
culture found in this study is difficult to evaluate. 
Because it is likely that endothelial cells would be at 
least as sensitive as fibroblasts, it is possible to 
postulate that: the high concentrations of rifampicin 
in the sewing ring of an implanted, impregnated 
valve may impair or delay initial endothelialization 
if such occurs in the first several days. The clinical 
significance of this is questionable because fibro- 
blastic penetration i to parts of the sewing ring may 
be more important and this does not begin to take 
place for several days. In practice the effect may be 
negligible; however, it is beyond the scope of this 
study to address whether this would cause an in- 
crease in the prevalence of periprosthetic leakage 
caused by the early temporary inhibition of endo- 
thelialization. 
This study has shown that rifampicin can be 
satisfactorily incorporated into the sewing ring ma- 
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Fig. 2. Loss of rifampicin from commercially available 
gelatin-sealed and collagen-sealed Dacron material mea- 
sured as antistaphylococcal activity (inhibition of growth). 
terial of the St. Jude Medical heart valve and that by 
first autoclaving the material in blood, antistaphylo- 
coccal activity is retained for at least 5 days in the 
experimental animal. Rifampicin impregnation of 
sewing ring material after autoclaving in 20% albu- 
min yields similar antistaphylococcal activity for 2 
days in vivo but significantly less activity by 4 days. 
Both of these methods of impregnating rifampicin 
into the sewing ring material of the St. Jude Medical 
heart valve allowed significantly better etention of 
antistaphylococcal activity than observed with either 
rifampicin-impregnated gelatin-sealed or collagen- 
sealed Dacron material. 
Ideally a prospective clinical trial should be done to 
determine the beneficial effects and any possible det- 
rimental effects of this procedure, which may be based 
on the following suggested clinical application. 
Possible clinical application and suggested pro- 
tocol. The patient is one with endocarditis who 
requires valve replacement with a prosthetic valve. 
After the appropriate-sized mechanical valve is se- 
lected, it is soaked in heparinized autologous blood 
and then autoclaved for 2 minutes. The valve is 
carefully cleaned of all particulate matter and im- 
mersed in the rifampicin solution at room temper- 
ature for 15 minutes. This solution is composed of 
rifampicin in 0.9% NaC1 made up to a concentration 
of 60 mg/ml. During this waiting period multiple 
interrupted polypropylene sutures can be placed in 
the anulus in the usual manner. Polypropylene 
rather than braided suture material is used because 
it is less liable to become a nidus for residual 
infection. The rifampicin-impregnated valve is then 
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inserted. Appropriate systemic administration of 
antibiotics is continued according to the nature and 
extent of the endocarditis. 
If passage of the needle through the Dacron 
fabric sewing rim is considered too difficult, accept- 
able antistaphylococcal activity can still be obtained 
by soaking the valve in 20% albumin instead of 
autologous blood before autoclaving the valve. This 
activity is as good initially but diminishes over a 
shorter interval. 
This protocol is also eminently suitable for Da- 
cron fabric tube arterial grafts in the presence of 
surrounding infection. Both experimental nd clini- 
cal experiences with arterial grafts have been re- 
ported,6, 7,10, 12-14 and the use of antibiotic-soaked 
grafts in vascular operations is reasonably well es- 
tablished. 
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